Relapsed or refractory lymphoma
Treatment options in Shanghai

Further chemotherapy or antibody-based combinations may be considered, and high-dose treatment with autologous stem-cell support is a possible pathway for selected patients. An autologous transplant uses the patient's own stem cells; it is not the same intervention as CAR-T. The decision involves more than whether stem cells can be collected: response to treatment, fitness and the expected burden of intensive treatment must be considered. Ask what the proposed initial regimen is meant to achieve and which result would lead to transplantation or a different strategy. A sequence should include a contingency if disease control is insufficient.

CAR-T uses T cells modified to recognise a target on cancer cells. For suitable large B-cell lymphoma cases, it can produce meaningful disease control, but it does not work for everyone and relapse remains possible. Collection, manufacturing, treatment preparation, infusion and monitoring are separate stages. Manufacturing takes time; ask how the team would manage disease while waiting and what happens if the intended pathway cannot proceed. Serious risks include cytokine release syndrome, neurological toxicity and infection. The suitability decision must include the ability to monitor and manage these complications, not simply eligibility to receive an infusion.

Depending on the prior treatment and clinical situation, antibody-based or targeted regimens, a clinical trial or symptom-directed treatment may be discussed. Their goals and burdens differ: some aim for sustained disease control, while others may primarily relieve symptoms when intensive therapy is unsuitable. Radiotherapy can have a role for selected symptoms or sites, without treating it as a universal systemic solution. Ask what evidence applies to your subtype and treatment stage. Trial participation has separate inclusion criteria and is not a guaranteed fallback.